CRISPR correction of a homozygous low‐density lipoprotein receptor mutation in familial hypercholesterolemia induced pluripotent stem cells

Linda Omer, Elizabeth A. Hudson, Shirong Zheng, James B. Hoying, Yuan Shan, Nolan L. Boyd – 16 October 2017 – Familial hypercholesterolemia (FH) is a hereditary disease primarily due to mutations in the low‐density lipoprotein receptor (LDLR) that lead to elevated cholesterol and premature development of cardiovascular disease. Homozygous FH patients (HoFH) with two dysfunctional LDLR alleles are not as successfully treated with standard hypercholesterol therapies, and more aggressive therapeutic approaches to control cholesterol levels must be considered.

Neutrophil gelatinase‐associated lipocalin level is a prognostic factor for survival in rat and human chronic liver diseases

Kyoko Yoshikawa, Motoh Iwasa, Akiko Eguchi, Shinichi Kojima, Naohiko Yoshizawa, Mina Tempaku, Ryosuke Sugimoto, Norihiko Yamamoto, Kazushi Sugimoto, Yoshinao Kobayashi, Hiroshi Hasegawa, Yoshiyuki Takei – 16 October 2017 – Chronic liver disease patients often have complications, such as hepatocellular carcinoma (HCC) and acute bacterial infection. Model for end‐stage liver disease and Child‐Pugh scores are useful prognostic factors for chronic liver diseases but not for all chronic conditions, such as HCC.

Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice

Mei Zhou, R. Marc Learned, Stephen J. Rossi, Alex M. DePaoli, Hui Tian, Lei Ling – 16 October 2017 – Nonalcoholic fatty liver disease (NAFLD) is an increasingly prevalent chronic liver disease for which no approved therapies are available. Despite intensive research, the cellular mechanisms that mediate NAFLD pathogenesis and progression are poorly understood.

Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease

Michael S. Middleton, Mark L. Van Natta, Elhamy R. Heba, Adina Alazraki, Andrew T. Trout, Prakash Masand, Elizabeth M. Brunt, David E. Kleiner, Edward Doo, James Tonascia, Joel E. Lavine, Wei Shen, Gavin Hamilton, Jeffrey B. Schwimmer, Claude B.

Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis

Ju Dong Yang, Ajitha Mannalithara, Andrew J. Piscitello, John B. Kisiel, Gregory J. Gores, Lewis R. Roberts, W. Ray Kim – 12 October 2017 – Surveillance for hepatocellular carcinoma (HCC) has been recommended in patients with cirrhosis. In this study, we examined the extent to which the competing risk of hepatic decompensation influences the benefit of HCC surveillance by investigating the impact of availability of liver transplantation (LTx) and the rate of progression of hepatic decompensation on survival gain from HCC surveillance.

Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis

Ju Dong Yang, Ajitha Mannalithara, Andrew J. Piscitello, John B. Kisiel, Gregory J. Gores, Lewis R. Roberts, W. Ray Kim – 12 October 2017 – Surveillance for hepatocellular carcinoma (HCC) has been recommended in patients with cirrhosis. In this study, we examined the extent to which the competing risk of hepatic decompensation influences the benefit of HCC surveillance by investigating the impact of availability of liver transplantation (LTx) and the rate of progression of hepatic decompensation on survival gain from HCC surveillance.

Subscribe to